Discover the top 30 companies transforming the biosimilars market, including Sandoz Group AG, Pfizer Inc., Amgen Inc., and other industry leaders. Backed by a market projected to grow from $35.04 billion to $72.29 billion by 2035 at a CAGR of 7.5%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Biosimilars Companies

Sandoz Group AG

Sandoz Group AG is a global leader in generic and biosimilar medicines, recently transitioning to a standalone “pure-play” entity to sharpen its focus on expanding patient access to affordable biologics. With a heritage spanning over 140 years, the company pioneered the biosimilars field by launching the world’s first biosimilar, Omnitrope, in 2006. Today, Sandoz maintains a robust portfolio of 13 marketed biosimilars and an industry-leading pipeline of 27 candidates targeting high-need therapeutic areas such as oncology, immunology, endocrinology, and neurology. By vertically integrating its development and manufacturing units, Sandoz continues to drive innovation and healthcare savings, reaching approximately one billion patients annually across the globe.

Pfizer Inc.

Pfizer Inc. is a premier biopharmaceutical corporation that has successfully leveraged its extensive legacy in oncology and immunology to establish one of the largest biosimilar portfolios in the industry. The company focuses on delivering high-quality, lower-cost alternatives to critical biologics, particularly through its monoclonal antibody (mAb) offerings like Zirabev, Ruxience, and Trazimera. Pfizer’s biosimilar strategy is supported by a sophisticated global manufacturing network and a commitment to “totality of evidence” in clinical development, ensuring that its products meet the same rigorous standards as its innovator biologics. Beyond manufacturing, Pfizer actively advocates for policy reforms to improve biosimilar reimbursement and uptake, aiming to enhance healthcare equity and sustainability worldwide.

Amgen Inc.

Amgen Inc. is a global biotechnology pioneer that has utilized its four decades of expertise in biologics innovation to become a dominant force in the biosimilars market. The company has invested over $2 billion in a diverse portfolio of 11 approved or pipeline biosimilar medicines, primarily focusing on oncology, inflammation, and rare diseases. Amgen distinguishes itself through its “biologics first” mindset, applying the same high-standard manufacturing and quality control processes to its biosimilars as it does to its novel therapies. By providing comprehensive patient support programs and educational resources for healthcare providers, Amgen plays a critical role in building trust and ensuring the reliable supply of cost-effective biologic treatments in highly competitive global markets.

Celltrion Inc.

Celltrion Inc. is a leading South Korean biopharmaceutical company specialized in the research, development, and large-scale manufacturing of monoclonal antibody biosimilars. Renowned for its world-class production capabilities, Celltrion operates some of Asia’s largest FDA-certified cGMP animal cell culture facilities and was the first to receive EMA approval for a biosimilar monoclonal antibody (Remsima). The company’s “one-stop” integrated model covers the entire value chain from R&D and clinical trials to global distribution through its affiliate, Celltrion Healthcare. With a strong commercial presence in over 100 countries and a growing portfolio that includes Truxima and Herzuma, Celltrion continues to disrupt the global market by providing high-quality, affordable treatments for autoimmune diseases and various cancers.

Biocon

Biocon is a global biopharmaceutical powerhouse and India’s leading biosimilars company, recently transformed into a fully integrated global leader through its strategic acquisition of Viatris’ biosimilars business. Operating primarily through its subsidiary, Biocon Biologics, the company serves patients in over 120 countries, leveraging state-of-the-art manufacturing hubs in India and Malaysia. Biocon is recognized for its “affordable innovation” model, having pioneered cost-efficient recombinant human insulin and established one of the industry’s most comprehensive oncology and immunology portfolios. With a commitment to reaching over 6 million patients annually, Biocon continues to scale its commercial engine in advanced markets while maintaining a dominant share in emerging regions, driving global health equity through science-led R&D and vertical integration.

Download PDF Brochure:“Click Here”